Interleukin-4 and -13 Inhibit Tumor Necrosis Factor-alpha mRNA Translational Activation in Lipopolysaccharide-induced Mouse Macrophages*

(Received for publication, September 5, 1996, and in revised form, March 13, 1997)

Tatjana Mijatovic Dagger , Véronique Kruys §, Daniel Caput , Patrick Defrance and Georges Huez

From the Laboratoire de Chimie Biologique, Département de Biologie Moléculaire, Université Libre de Bruxelles, 1640 Rhode Saint Genèse, Brussels, Belgium and  Sanofi Elf Biorecherches, 31676 Labège, Cedex, France

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

The production of tumor necrosis factor-alpha (TNF-alpha ) by lipopolysaccharide (LPS)-stimulated macrophages can be markedly inhibited by the two closely related cytokines, interleukin (IL)-4 and IL-13. To investigate the molecular mechanism of this inhibition, we analyzed the effect of the two cytokines on TNF-alpha production and TNF-alpha mRNA accumulation in the mouse macrophage cell lines RAW 264.7 and J774 stimulated by LPS. Whereas LPS-induced TNF-alpha production is strongly suppressed by both cytokines, TNF-alpha mRNA accumulation is not significantly affected, indicating that IL-4 and IL-13 induce a translational repression of TNF-alpha mRNA. Transfection of reporter gene constructs containing different regions of the TNF-alpha gene revealed that the inhibitory action of IL-4 and IL-13 is mediated by the UA-rich sequence present in the TNF-alpha mRNA 3'-untranslated region.


INTRODUCTION

Tumor necrosis factor-alpha (TNF-alpha )1 is a pleiotropic cytokine secreted by different cell types including macrophages, mastocytes, T and B lymphocytes, and natural killer cells in response to various stimuli (lipopolysaccharide (LPS), viruses, parasites, etc.) (1). A wide variety of cell types express TNF-alpha receptors, and the pleiotropism of TNF-alpha results from the complexity of the signal transduction pathways that are activated by its receptors. TNF-alpha is characterized by cytostatic and cytolytic effects on tumor cells of different origins (2), by antiviral properties (3), and by its important role in the activation of the immune system upon host invasion (4). TNF-alpha has also been identified as a major mediator of inflammatory processes, one of the most dramatic being Gram-negative endotoxic shock (1). Indeed, upon exposure to LPS or other agents simulating host invasion, macrophages produce large amounts of TNF-alpha that are released in the circulatory system. High levels of circulating TNF-alpha trigger a state of shock and tissue injury that carries an extremely high mortality rate (1).

The expression of the TNF-alpha gene in mouse macrophages is regulated at the transcriptional (5, 6) and translational (1) levels. In resting macrophages, TNF-alpha synthesis is low because TNF-alpha gene transcription is weak and TNF-alpha mRNA translation is severely repressed. The translational repression is mediated by the UA-rich sequence present in the TNF-alpha mRNA 3'-untranslated region (1). Macrophage activation by LPS results in NF-kappa B-dependent activation of TNF-alpha gene transcription, derepression of TNF-alpha mRNA translation, and secretion of TNF-alpha protein. TNF-alpha production by macrophages can be down-regulated by various agents including cytokines like IL-4 and IL-13 (7, 12). IL-4 and IL-13 are two closely related cytokines that are synthesized mainly by activated T lymphocytes (7, 8). Both cytokines share many biological activities including the activation of B cell proliferation, IgE switching, and inhibition of inflammatory cytokine production (9-11). TNF-alpha is one of the major inflammatory cytokines being repressed by IL-4 and IL-13. However, the molecular mechanism of this regulation has not been elucidated. In this study, we investigated the mechanism by which IL-4 and IL-13 down-regulate TNF-alpha production in LPS-stimulated mouse RAW 264.7 and J774 macrophages. We show that in these cell types, IL-4 and IL-13 inhibit LPS-induced TNF-alpha production mainly at the translational level. Furthermore, down-regulation of TNF-alpha mRNA translation by IL-4 and IL-13 is mediated by the UA-rich sequence present in its 3'-untranslated region.


MATERIALS AND METHODS

Reagents

LPS from Escherichia coli (strain 0.127:B8) was obtained from Sigma. [alpha -32P]UTP (800 Ci/mmol) and [14C]chloramphenicol (56 mCi/mmol) were purchased from Amersham Life Science, Inc. Murine recombinant IL-4 and TNF-alpha were purchased from Genzyme. Purified murine IL-13 was obtained from Sanofi Elf Biorecherches, Labège, France.

DNA Constructs

Both reporter constructs used in this study have been described elsewhere: CMV3'TNF in Ref. 13 and CMV3'TNFUA- in Ref. 14, referred to as construct 3.

Cell Culture, Transfection, and Treatments

The murine macrophage cell lines RAW 264.7 and J774 were obtained from the American Type Culture Collection. The cells were maintained in Dulbecco's modified Eagle's medium containing 5% fetal bovine serum (FBS Myoclone Super Plus, Life Technologies, Inc.) and 1% penicillin/streptomycin.

RAW 264.7 cells were cotransfected with each of the described constructs and pSV2Neo as described (15). Cells were first selected for 1 day with 0.3 mg/ml G418 sulfate, for 1 day with 0.6 mg/ml, and for 2 weeks with 1 mg/ml. The resistant clones were then pooled. The cells were stimulated simultaneously with LPS (10 ng/ml) and IL-4 (5 ng/ml) or IL-13 (5 ng/ml) unless otherwise specified.

Measurement of TNF-alpha Production

TNF-alpha levels were measured in cell supernatants by sandwich enzyme-linked immunosorbent assay using a polyclonal rabbit anti-mouse TNF-alpha antibody for coating and the same biotinylated polyclonal antibody for detection (generously provided by Dr. W. Buurman, University of Limburg Maastricht, The Netherlands).

CAT Assay

CAT assays were performed as described (17), and quantification of CAT activity was performed with a Molecular Dynamics PhosphorImager.

Northern Blot Analysis

Northern blot analysis was performed as described (16) using 10 and 20 µg of total cytoplasmic RNA for TNF-alpha and CAT mRNA detection, respectively. Blots were hybridized with antisense riboprobes for TNF-alpha and CAT mRNAs (16, 17). For quantification, the blots were rehybridized with a glyceraldehyde-3-phosphate dehydrogenase antisense riboprobe. RNA quantification was achieved by normalizing the radioactive signal corresponding to TNF-alpha mRNA to that of glyceraldehyde-3-phosphate dehydrogenase in the same RNA sample.


RESULTS

Inhibition of LPS-induced TNF-alpha Production by IL-4 and IL-13 in RAW 264.7 and J774 Mouse Macrophages

RAW 264.7 mouse macrophages produce large amounts of TNF-alpha in response to LPS. Moreover, the transcriptional and post-transcriptional regulation of TNF-alpha biosynthesis by LPS is well characterized in this cell line. Therefore, RAW 264.7 cells provided an appropriate system to analyze the mechanism by which IL-4 and IL-13 suppress LPS-induced TNF-alpha production. We also analyzed the mechanism by which these cytokines down-regulate LPS-induced TNF-alpha production in J774 cells, which produce high levels of TNF-alpha upon LPS stimulation.

A recent study has shown that depending on the time of exposure to IL-4 or IL-13 relative to LPS stimulation, IL-4 and IL-13 have either inhibitory or stimulatory effects on LPS-induced TNF-alpha production in human peripheral blood mononuclear cells (18). When added to the cell culture 20 h or more before LPS stimulation, IL-4 and IL-13 prime LPS-induced TNF-alpha production, whereas when added simultaneously or a few hours before LPS stimulation, IL-4 and IL-13 exert a marked inhibitory effect on the production of this cytokine (18). Therefore, before analyzing the mechanism by which these cytokines inhibit LPS-induced TNF-alpha production, we verified that IL-4 and IL-13, when added to the cell culture at the same time as LPS, could inhibit TNF-alpha production in RAW 264.7 and J774 cells. We performed experiments in which increasing concentrations of each cytokine were added to RAW 264.7 or J774 cell cultures simultaneously with LPS. TNF-alpha production was assayed by enzyme-linked immunosorbent assay using a polyclonal anti-mouse TNF-alpha antibody to measure the totality of TNF-alpha produced in response to the various treatments. As shown in Fig. 1, LPS-induced TNF-alpha production in RAW 264.7 cells was inhibited by both cytokines in a dose-dependent manner, reaching 72 and 63% inhibition at the highest doses of IL-4 and IL-13 tested, respectively (IL-4, 5 ng/ml; and IL-13, 5 ng/ml). Similarly, the highest doses of IL-4 and IL-13 inhibited TNF-alpha production in LPS-stimulated J774 cells by 65 and 67%, respectively.


Fig. 1. Inhibition of LPS-induced TNF-alpha production by increasing doses of IL-4 (A) or IL-13 (B) in RAW 264.7 (solid bars) and J774 (striped bars) cells. Cells were plated at a density of 1.5 × 105 cells/well in 24-well plates. When the cells were adherent, they were either untreated or treated with LPS (10 ng/ml) alone or in combination with IL-4 or IL-13 at the indicated concentrations. After 6 h of incubation, the cell culture media were harvested to measure TNF-alpha production. The induction of TNF-alpha production by LPS in the presence of either cytokine is expressed in percent, attributing 100% to the level of TNF-alpha produced by cells treated by LPS alone in comparison with the level of TNF-alpha produced by unstimulated cells. Results are the means ± S.E. from three separate experiments.
[View Larger Version of this Image (32K GIF file)]

IL-4 and IL-13 Inhibit LPS-induced TNF-alpha Production at the Translational Level

TNF-alpha production by LPS-stimulated mouse macrophages results from a combination of TNF-alpha gene transcriptional activation and TNF-alpha mRNA translational derepression. To determine at which level IL-4 and IL-13 inhibit LPS-induced TNF-alpha production, we analyzed LPS-induced TNF-alpha mRNA accumulation in the presence or absence of each cytokine. Since TNF-alpha mRNA accumulation peaks 2 h after LPS addition to the cell culture (19), we studied the effect of IL-4 and IL-13 on TNF-alpha mRNA accumulation at this time point after LPS induction. We observed that whereas both cytokines inhibited LPS-induced TNF-alpha production, TNF-alpha mRNA accumulation was not affected by IL-4 and IL-13 in RAW 264.7 cells (Fig. 2). In J774 cells, both IL-4 and IL-13 markedly suppressed LPS-induced TNF-alpha production, as previously observed. Northern blot analysis of TNF-alpha mRNA revealed that LPS-induced TNF-alpha mRNA accumulation was slightly reduced by IL-4 and IL-13 (Fig. 3). However, this 13% decrease cannot account by itself for the reduction of TNF-alpha production, which reached 60 and 80% in response to IL-4 and IL-13, respectively. Altogether, these results indicate that the suppressive effect of IL-4 and IL-13 on TNF-alpha biosynthesis is mostly if not completely exerted at the translational level in both cell lines.


Fig. 2. Simultaneous analysis of TNF-alpha production and TNF-alpha mRNA accumulation in LPS-stimulated RAW 264.7 cells in the presence or absence of IL-4 or IL-13. Cells were plated at a density of 2 × 106 cells/well in six-well plates. When the cells were adherent, they were either untreated or treated with LPS (10 ng/ml) alone or in combination with IL-4 (5 ng/ml) or IL-13 (5 ng/ml) or treated with either cytokine alone. After 2 h of incubation, the culture media were harvested to measure TNF-alpha production (A), and the cells were collected to extract cytoplasmic RNA for Northern blot analysis (B). The induction of TNF-alpha production by LPS in the presence of either cytokine is expressed in percent, attributing 100% to the level of TNF-alpha produced by cells treated by LPS alone in comparison with the level of TNF-alpha produced by unstimulated cells. Results are the means ± S.E. of six separate experiments. TNF-alpha mRNA accumulation was quantified as described under "Materials and Methods," attributing 100% to the TNF-alpha mRNA level obtained for cells treated with LPS alone. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an internal control. Similar results were obtained in six separate experiments, with a maximal variation of 5% in the TNF-alpha mRNA level.
[View Larger Version of this Image (17K GIF file)]


Fig. 3. Simultaneous analysis of TNF-alpha production (A) and TNF-alpha mRNA accumulation (B) in LPS-stimulated J774 cells in the presence or absence of IL-4 or IL-13. The induction of TNF-alpha production by LPS in the presence of either cytokine is expressed in percent, attributing 100% to the level of TNF-alpha produced by cells treated by LPS alone in comparison with the level of TNF-alpha produced by unstimulated cells. Results are the means ± S.E. of four separate experiments. TNF-alpha mRNA accumulation was quantified as described under "Materials and Methods," attributing 100% to the TNF-alpha mRNA level obtained for cells treated with LPS alone. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an internal control. Similar results were obtained in four separate experiments, with a maximal variation of 10% in the TNF-alpha mRNA level.
[View Larger Version of this Image (20K GIF file)]

Down-regulation of TNF-alpha mRNA Translation by IL-4 and IL-13 Is Mediated by the UA-rich Sequence Present in TNF-alpha mRNA

As the 3'-untranslated region of the TNF-alpha mRNA plays a central role in the translational control of TNF-alpha gene expression, we analyzed the effect of IL-4 and IL-13 on the expression of a stably transfected CAT reporter gene containing this sequence (CMV3'TNF; Fig. 4) in RAW 264.7 cells. Indeed, former studies showed that in RAW 264.7 cells transfected with this construct, LPS stimulates the expression of the reporter gene by acting only at the translational level (13). In unstimulated RAW 264.7 cells, the presence of the CMV promoter led to the constitutive accumulation of CMV3'TNF mRNA as evaluated by Northern blotting, but this mRNA was poorly translated in CAT protein (Fig. 5A). Upon stimulation with LPS, translational derepression resulted in CAT protein accumulation without significant variation of the CMV3'TNF mRNA. Exposure of the CMV3'TNF-transfected cells to LPS in combination with IL-4 or IL-13 markedly reduced the accumulation of CAT activity (Fig. 5A) without affecting the level of CMV3'TNF mRNA. In contrast, IL-4 and IL-13 had no effect on the expression of the CMV3'TNFUA- construct, in which the UA-rich sequence is specifically deleted (see Figs. 4 and 5B). As a control, we verified that the inhibition of LPS-induced TNF-alpha production by IL-4 and IL-13 in both transfected cell lines was equivalent to that observed in untransfected RAW 264.7 cells (data not shown). These results indicate that IL-4 and IL-13 suppress the expression of the CMV3'TNF reporter gene at the translation level and require the presence of the UA-rich sequence to exert their inhibitory action on TNF-alpha mRNA translation.


Fig. 4. Schematic representation of the CAT reporter gene constructs CMV3'TNF and CMV3'TNFUA-. UTR, untranslated region.
[View Larger Version of this Image (15K GIF file)]


Fig. 5. IL-4 and IL-13 inhibit LPS-induced translation of a CAT reporter construct containing the full-length TNF-alpha 3'-untranslated region. A, CAT activity and Northern blot analysis of CAT mRNA accumulation in RAW 264.7 cells stably transfected with the CMV3'TNF construct after stimulation with LPS alone or in combination with IL-4 or IL-13; B, CAT activity and Northern blot analysis of CAT mRNA accumulation in RAW 264.7 cells stably transfected with the CMV3'TNFUA- construct after treatment with LPS alone or in combination with IL-4 or IL-13. Cells were plated at a density of 10 × 106 cells in 10-cm dishes. When the cells were adherent, they were either untreated or treated with LPS (10 ng/ml) alone or in combination with IL-4 (5 ng/ml) or IL-13 (5 ng/ml). After 3 h of incubation, the cells were harvested. 106 cells were used to assay CAT activity, and 9 × 106 cells were used to extract cytoplasmic RNA for Northern blot analysis. CAT production is expressed in percent, attributing 100% to the level of CAT activity produced by the cells treated with LPS alone. The results show one representative out of three independent experiments. A maximal 10% variation was observed in the level of CAT mRNA accumulation and in the degree of inhibition of CAT protein production by IL-4 and IL-13. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; AcCM, acetylated forms of chloramphenicol; CM, chloramphenicol.
[View Larger Version of this Image (27K GIF file)]


DISCUSSION

It is now well established that in monocytes/macrophages, IL-4 and IL-13 mediate several similar functions, among which one of the major is the inhibition of proinflammatory cytokine production. Indeed, both IL-4 and IL-13 inhibit the production of several cytokines including IL-1alpha , IL-1beta , IL-6, IL-12, macrophage inflammatory protein-alpha , granulocyte/macrophage colony-stimulating factor, granulocyte colony-stimulating factor, interferon-alpha , and TNF-alpha by monocytes/macrophages activated with LPS (7, 10, 12, 20). The inhibitory effect of IL-4 and IL-13 on the production of TNF-alpha has been demonstrated in human peripheral blood monocytes (7, 10-12, 21, 22), human alveolar macrophages (23), murine bone marrow macrophages (11, 20) and murine peritoneal macrophages (24). The mechanism by which IL-4 and IL-13 inhibit LPS-induced TNF-alpha production in monocytes/macrophages is still controversial. For instance, several studies show that IL-4 and IL-13 decrease LPS-induced TNF-alpha mRNA accumulation in human peripheral blood mononuclear cells (7, 21, 22). However, one report describes that in mouse peritoneal macrophages, IL-4 does not modify TNF-alpha mRNA accumulation in response to LPS (24). The expression of the TNF-alpha gene in macrophages is regulated both at the transcriptional and post-transcriptional levels (1). In unstimulated mouse macrophages, TNF-alpha production is severely repressed both at the transcriptional and translational levels. Indeed, under these conditions, TNF-alpha gene transcription is poor, and TNF-alpha mRNA translation is blocked. This translational repression is mediated by the UA-rich sequence located in the 3'-untranslated region of TNF-alpha mRNA. Macrophage activation by LPS leads to a 50-fold increase in TNF-alpha gene transcription and a 200-fold increase in TNF-alpha mRNA translation, leading to an overall 10,000-fold increase in TNF-alpha biosynthesis (1). Translational regulation of TNF-alpha mRNA also plays an important role under other circumstances. Indeed, LPS tolerance, which is characterized by an impaired TNF-alpha production in response to a secondary LPS challenge, is mainly due to a defective translation of TNF-alpha mRNA (14). Furthermore, production of TNF-alpha in response to infection by several viruses (Sendai virus, Newcastle disease virus, vesicular stomatitis virus, vaccinia virus, and Mengo virus) results to a great extent from TNF-alpha mRNA translational activation (25).

In our study, we aimed at determining the mechanism by which IL-4 and IL-13 inhibit LPS-induced TNF-alpha production in the mouse macrophage cell line RAW 264.7, in which the regulation of TNF-alpha biosynthesis is well characterized. Furthermore, we also investigated this regulatory mechanism in another mouse macrophage cell line, J774, which also produces high levels of TNF-alpha in response to LPS. We first verified that IL-4 and IL-13 down-regulate TNF-alpha production in both cell types when added to the cell culture at the same time as LPS. We then demonstrated that under these conditions, both cytokines inhibit LPS-induced TNF-alpha production without significantly affecting TNF-alpha mRNA accumulation. Therefore, we conclude that IL-4 and IL-13 down-regulate TNF-alpha gene expression at the translational level. By analyzing the effect of IL-4 and IL-13 on the expression of CAT reporter DNA constructs with or without the TNF-alpha mRNA UA-rich sequence in RAW 264.7 cells, we show that both IL-4 and IL-13 exert their inhibitory action on mRNA translation through the intermediate of this UA-rich sequence. Recently, we have identified in RAW 264.7 cells a protein complex that binds the TNF-alpha mRNA UA-rich sequence upon stimulation with LPS (26). The LPS-induced binding of this complex to the UA-rich sequence requires tyrosine phosphorylation since it is blocked by the protein tyrosine phosphorylation inhibitor herbimycin A. The observation that IL-4 and IL-13 affect TNF-alpha mRNA translation suggests that IL-4 and IL-13 might interfere with the binding of this protein complex to the UA-rich sequence upon LPS stimulation. The mechanism by which this phenomenon might occur is still speculative. However, it is well known that stimulation of macrophages by LPS promotes tyrosine phosphorylation of various members of the serine/threonine mitogen-activated protein kinase family, including mitogen-activated protein kinases, mitogen-activated protein kinase-like p38, and its human homologs CSBP1 and CSBP2, resulting in an increase in their kinase activity (27-32). Interestingly, inhibitors of CSBP1 and CSBP2 kinase activity specifically impair LPS-induced TNF-alpha mRNA translation by preventing TNF-alpha mRNA recruitment into polysomes upon LPS stimulation (33). These observations indicate that p38 and CSBPs are the LPS-signaling intermediates that mediate TNF-alpha mRNA translational activation most probably by triggering the binding of the protein complex to the UA-rich sequence.

How do IL-4 and IL-13 down-regulate LPS-induced TNF-alpha mRNA translation? Both cytokines share a common receptor subunit, IL-4 receptor-alpha , which is essential for intracellular signaling (34). Upon IL-4 or IL-13 stimulation, IL-4 receptor-alpha becomes phosphorylated on tyrosine residues and recruits several signaling proteins including 4PS (also called IRS-2). 4PS, which also becomes phosphorylated on tyrosine residues, forms a signaling complex containing phosphatidylinositol 3-kinase, the adapter molecules GRB/Sos and Nck, and the tyrosine phosphatase PTP1D (also known as SH-PTP2 or Syp) (35, 36). So far, no downstream signals originating from GRB/Sos, Nck, and PTP1D have been observed upon IL-4/IL-13 stimulation, and the significance of their recruitment by 4PS remains unclear. We can speculate that upon IL-4 or IL-13 stimulation, the tyrosine phosphatase activity of PTP1D might down-regulate the kinase activity of p38 or CSBP1 and CSBP2 by controlling their phosphorylation status. Consequently, the LPS-induced binding of the protein complex to the UA-rich sequence and TNF-alpha mRNA translation would be inhibited.


FOOTNOTES

*   This work was supported in part by Grant 3.4586.93 from the Fund for Medical Scientific Research (Belgium), Grant D.4512.93 from the "Fonds Dehousse," Grant 9499/181 from the "Actions de Recherches Concertées," and Grant BIO4-CT95-0045 from the European Community Biotechnology Program.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    Supported by grants from the A. & D. Van Buuren Foundation and from the de Meurs-Francois Foundation.
§   To whom correspondence should be addressed: Lab. de Chimie Biologique, Dépt. de Biologie Moléculaire, Université Libre de Bruxelles, 67, rue des Chevaux, 1640 Rhode Saint Genèse, Brussels, Belgium. Tel.: 322-650-9816; Fax: 322-650-9839; E-mail: vkruys @dbm.ulb.ac.be.
1   The abbreviations used are: TNF-alpha , tumor necrosis factor-alpha ; LPS, lipopolysaccharide; IL, interleukin; CMV, cytomegalovirus; CAT, chloramphenicol acetyltransferase; CSBP, CSAID (cytokine-suppressive antiinflammatory drug) binding protein.

ACKNOWLEDGEMENTS

We thank Dr. W. Buurman for providing the polyclonal rabbit anti-mouse TNF-alpha antibody used in the mouse TNF-alpha enzyme-linked immunosorbent assay. We thank Drs. B. Beutler, F. Bazzoni, and J. Han for providing the DNA constructs. We thank Dr. Louis Droogmans for critical reading of the manuscript.


REFERENCES

  1. Beutler, B. (1992) Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, Raven Press, New York
  2. Sugarman, B. J., Aggrawal, B. B., Figari, I. S., Hass, P. E., Palladino, M. A., Jr., and Shepard, H. M. (1985) Science 230, 943-945 [Medline] [Order article via Infotrieve]
  3. Mire Sluis, A. (1993) Trends Biotechol. 11, 74-77 [Medline] [Order article via Infotrieve]
  4. Beutler, B., and Cerami, A. (1988) Biochemistry 27, 7575-7582 [Medline] [Order article via Infotrieve]
  5. Collart, M., Bauerle, P., and Vassalli, P. (1990) Mol. Cell. Biol. 10, 1498-1506 [Medline] [Order article via Infotrieve]
  6. Read, M. A., Whitly, M. Z., Williams, A. J., and Collins, T. (1994) J. Exp. Med. 179, 503-512 [Abstract]
  7. Minty, A., Chalon, P., Derocq, J.-M., Dumont, X., Guillemont, J.-C., Kaghad, M., Labit, C., Leplatois, P., Liauzun, P., Miloux, B., Minty, C., Casellas, P., Loison, G., Lupker, J., Shire, D., Ferrara, P., and Caput, D. (1993) Nature 362, 248-250 [CrossRef][Medline] [Order article via Infotrieve]
  8. O'Garra, A., and Spits, H. (1993) Res. Immunol. 144, 567-651
  9. de Vries, J. E., Punnonen, J., Cocks, B. G., de Waal Malefyt, R., and Aversa, G. (1993) Res. Immunol. 144, 597-601 [Medline] [Order article via Infotrieve]
  10. de Waal Malefyt, R., Figdor, C. G., Huijbens, R., Mohan-Peterson, S., Bennett, B., Culpepper, J., Dang, W., Zurawski, G., and de Vries, J. E. (1993) J. Immunol. 151, 6370-6381 [Abstract/Free Full Text]
  11. de Waal Malefyt, R., Figdor, C. G., and de Vries, J. E. (1993) Res. Immunol. 144, 629-633 [Medline] [Order article via Infotrieve]
  12. Hart, P. H., Jones, C. A., and Finlat-Jones, J. J. (1992) Immunology 76, 560-565 [Medline] [Order article via Infotrieve]
  13. Han, J., Huez, G., and Beutler, B. (1991) J. Immunol. 146, 1843-1848 [Abstract/Free Full Text]
  14. Marchant, A., Gueydan, C., Houzet, L., Amraoui, Z., Sels, A., Huez, G., Goldman, M., and Kruys, V. (1996) J. Inflamm. 46, 114-123 [Medline] [Order article via Infotrieve]
  15. Peppel, K., Vinci, J. M., and Baglioni, C. (1991) J. Exp. Med. 173, 349-355 [Abstract]
  16. Kruys, V., Thompson, P., and Beutler, B. (1993) J. Exp. Med. 177, 1383-1390 [Abstract]
  17. Gorman, C. M., Moffat, L. F., and Howard, B. H. (1982) Mol. Cell. Biol. 12, 1044-1051
  18. D'Andrea, A., Ma, X., Aste-Amezaga, M., Paganin, C., and Trinchieri, G. (1995) J. Exp. Med. 181, 537-546 [Abstract]
  19. Han, J., Beutler, B., and Huez, G. (1991) Biochim. Biophys. Acta 1090, 22-28 [Medline] [Order article via Infotrieve]
  20. Doherty, M. T., Kastelein, R., Menon, S., Andrade, S., and Coffman, R. L. (1993) J. Immunol. 151, 7151-7160 [Abstract/Free Full Text]
  21. Essner, R., Rhoades, K., Mcbride, H. W., Morton, L. D., and Economou, S. J. (1989) J. Immunol. 142, 3857-3861 [Abstract/Free Full Text]
  22. Hart, H. P., Vitti, F. G., Burgess, R. D., Whitty, A. G., and Piccoli, S. D. (1989) Proc. Natl. Acad. Sci. U. S. A. 86, 3803-3807 [Abstract]
  23. Sone, S., Yanagawa, H., Nishioka, Y., Ozino, E., Bhaskagan, G., Nii, A., Mizuno, K., Heike, Y., Ogushi, F., and Ogura, T. (1992) Eur. Respir. J. 5, 174-181 [Abstract]
  24. Gautam, S., Tebo, M. J., and Hamilton, A. T. (1992) J. Immunol. 148, 1725-1730 [Abstract/Free Full Text]
  25. Willeaume, V., Kruys, V., Mijatovic, T., and Huez, G. (1996) J. Inflamm. 46, 1-12
  26. Gueydan, C., Houzet, L., Marchant, A., Sels, A., Huez, G., and Kruys, V. (1996) Mol. Med. 2, 479-488 [Medline] [Order article via Infotrieve]
  27. Weinstein, S. L., Sanghera, J. S., Lemke, K., DeFranco, A. L., and Pelech, S. L. (1992) J. Biol. Chem. 267, 14955-14962 [Abstract/Free Full Text]
  28. Dong, Z., Qi, X., and Fidler, I. J. (1993) J. Exp. Med. 177, 1071-1077 [Abstract]
  29. Han, J., Lee, J. D., Tobias, P. S., and Ulevitch, R. J. (1993) J. Biol. Chem. 268, 25009-25014 [Abstract/Free Full Text]
  30. Geppert, T. D., Whitehurst, C. E., Thompson, P., and Beutler, B. (1994) Mol. Med. 1, 93-103 [Medline] [Order article via Infotrieve]
  31. Han, J., Lee, J. D., Bibbs, L., and Ulevitch, R. J. (1994) Science 265, 808-811 [Medline] [Order article via Infotrieve]
  32. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) Nature 372, 739-746 [CrossRef][Medline] [Order article via Infotrieve]
  33. Prichett, W., Hand, A., Shields, J., and Dunnington, D. (1995) J. Inflamm. 45, 97-105 [Medline] [Order article via Infotrieve]
  34. Duschl, A., and Sebald, W. (1996) Eur. Cytokine Netw. 7, 37-49 [Medline] [Order article via Infotrieve]
  35. Welham, M. J., Learmonth, L., Bone, H., and Shrader, J. W. (1995) J. Biol. Chem. 270, 12286-12296 [Abstract/Free Full Text]
  36. Pruett, W., Yuan, Y., Rose, E., Batzer, A. G., Harada, N., and Skolnik, E. Y. (1995) Mol. Cell. Biol. 15, 1778-1785 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.